We are live on ! Find out more
PCM

Peregrine Capital Management Portfolio holdings

AUM $3.08B
1-Year Est. Return 29.51%
This Fund
S&P 500
This Quarter Est. Return
+16.98%
1 Year Est. Return
+29.51%
3 Year Est. Return
+95.04%
5 Year Est. Return
+107.83%
10 Year Est. Return
+715.34%
AUM
$3.33B
AUM Growth
-$23.3M
Cap. Flow
-$449M
Cap. Flow %
-13.5%
Top 10 Hldgs %
22.9%
Holding
332
New
14
Increased
20
Reduced
227
Closed
14

Sector Composition

Rank Sector Weight
1 Technology 24.67%
2 Healthcare 16.61%
3 Financials 15.48%
4 Consumer Discretionary 13.51%
5 Industrials 11.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PRVA icon
226
Privia Health
PRVA
$2.81B
$5.14M 0.15%
223,239
-66,975
-23% -$1.5M
OPLN
227
Openlane
OPLN
$4.48B
$5.12M 0.15%
345,946
-60,527
-15% -$880K
SWTX
228
DELISTED
SpringWorks Therapeutics
SWTX
$4.96M 0.15%
136,009
-23,469
-15% -$613K
FOXF icon
229
Fox Factory Holding Corp
FOXF
$905M
$4.9M 0.15%
72,654
-4,806
-6% -$351K
LTHM
230
DELISTED
Livent Corporation
LTHM
$4.83M 0.15%
268,828
-88,984
-25% -$1.39M
ECPG icon
231
Encore Capital Group
ECPG
$1.98B
$4.79M 0.14%
94,330
-31,129
-25% -$1.41M
BLFS icon
232
BioLife Solutions
BLFS
$1.7B
$4.77M 0.14%
293,487
-50,663
-15% -$646K
RBA icon
233
RB Global
RBA
$16.6B
$4.55M 0.14%
68,065
-12,095
-15% -$777K
SRI icon
234
Stoneridge
SRI
$193M
$4.43M 0.13%
226,182
-73,489
-25% -$1.28M
STKL
235
DELISTED
SunOpta
STKL
$4.39M 0.13%
802,387
-138,148
-15% -$605K
SNDX icon
236
Syndax Pharmaceuticals
SNDX
$1.81B
$4.24M 0.13%
196,033
-23,941
-11% -$368K
ASTE icon
237
Astec Industries
ASTE
$989M
$4.19M 0.13%
112,641
-33,218
-23% -$1.22M
ADMA icon
238
ADMA Biologics
ADMA
$2.22B
$3.99M 0.12%
+882,983
New +$3.27M
LUCK
239
Lucky Strike Entertainment
LUCK
$897M
$3.85M 0.12%
271,563
-46,682
-15% -$513K
SRPT icon
240
Sarepta Therapeutics
SRPT
$1.92B
$3.71M 0.11%
38,463
-6,715
-15% -$644K
CHRS icon
241
Coherus Oncology
CHRS
$187M
$3.63M 0.11%
1,089,961
-288,606
-21% -$773K
ULCC icon
242
Frontier Group Holdings
ULCC
$1.59B
$3.32M 0.1%
608,425
-200,915
-25% -$879K
MNRO icon
243
Monro
MNRO
$365M
$2.72M 0.08%
92,876
-16,062
-15% -$452K
APPS icon
244
Digital Turbine
APPS
$1.58B
$2.63M 0.08%
384,054
-126,862
-25% -$708K
ADPT icon
245
Adaptive Biotechnologies
ADPT
$4.04B
$1.84M 0.06%
375,638
-64,317
-15% -$293K
MANH icon
246
Manhattan Associates
MANH
$11.4B
$1.83M 0.06%
8,510
-1,300
-13% -$275K
WCC
247
WESCO International
WCC
$17.8B
$1.55M 0.05%
8,918
NOVT icon
248
Novanta
NOVT
$6.34B
$1.49M 0.04%
8,838
MDC
249
DELISTED
M.D.C. Holdings, Inc.
MDC
$1.43M 0.04%
25,962
BG icon
250
Bunge Global
BG
$21.4B
$1.38M 0.04%
13,659

Similar funds

Peregrine Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Peregrine Capital Management held 332 positions worth $3.33B, down 0.69% from $3.35B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Peregrine Capital Management withdrew a net $449M in Q4 2023, closing 14 positions and reducing 227 holdings. Its most notable exit was Earthstone Energy Inc. Class A Common Stock, an estimated $12.5M position sold in full.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Peregrine Capital Management opened a new position in Permian Resources worth $9.15M.

  • Peregrine Capital Management's largest Q4 2023 buy was Permian Resources: 673,114 shares worth $9.15M.
  • Peregrine Capital Management added most to DoubleVerify in Q4 2023, an estimated $24.8M increase.
  • Peregrine Capital Management's biggest Q4 2023 reduction was HEICO Corp, cutting an estimated $20.6M.
  • Peregrine Capital Management fully exited Earthstone Energy Inc. Class A Common Stock in Q4 2023, selling an estimated $12.5M.
  • Peregrine Capital Management's ten largest holdings make up 23% of its $3.33B portfolio in Q4 2023.
  • Peregrine Capital Management opened 14 new positions and closed 14 in Q4 2023.
  • Peregrine Capital Management's portfolio value fell 0.69% quarter-over-quarter to $3.33B.

Based on Peregrine Capital Management's 13F filing for Q4 2023, filed 26 Jan 2024.